Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL4352730

Cn1c(C(=O)O)c(Nc2ccncc2)c2c(F)cccc21.O=C(O)C(F)(F)F

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK2 P49137 3/20 0.38
UBE2N P61088 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PTGER4 P35408 4/20 0.37
JAK2 O60674 2/20 0.37
JAK1 P23458 2/20 0.37
TYK2 P29597 2/20 0.37
HTT P42858 2/20 0.37
NOD2 Q9HC29 1/20 0.37
ROCK1 Q13464 4/20 0.37
AURKB Q96GD4 4/20 0.37
CHEK2 O96017 3/20 0.37
GSK3A P49840 3/20 0.37
GSK3B P49841 3/20 0.37
CDC42BPA Q5VT25 3/20 0.37
STK17A Q9UEE5 3/20 0.37
CSNK1G3 Q9Y6M4 3/20 0.37
CHEK1 O14757 2/20 0.37
DAPK3 O43293 2/20 0.37
RPS6KA5 O75582 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4351610 0.94 JAK2 (0.41) MAPKAPK2PTGER4JAK2JAK1TYK2
SCHEMBL4352734 0.84 MAPKAPK2 (0.36) MAPKAPK2PTGER4JAK2JAK1TYK2
SCHEMBL4335763 0.82 MAPKAPK2 (0.38) MAPKAPK2JAK2JAK1TYK2HTT
Trifluoroacetic Acid SCHEMBL4338507 0.76 UBE2N (0.42) MAPKAPK2UBE2NL3MBTL1JAK2JAK1
SCHEMBL13758173 0.75 PTGER4 (0.49) PTGER4MEN1ALDH1A1KMT2ATSHR
SCHEMBL4339781 0.74 MAPKAPK2 (0.37) MAPKAPK2JAK2JAK1TYK2HTT
SCHEMBL4334572 0.71 KDM4E (0.43) PTGER4HTTMEN1ALDH1A1KMT2A
Fumaric Acid SCHEMBL4496356 0.70 SLC6A2 (0.55) PTGER4MEN1ALDH1A1KMT2ACYP2C9
Maleic Acid SCHEMBL4496354 0.70 SLC6A2 (0.55) PTGER4MEN1ALDH1A1KMT2ACYP2C9
SCHEMBL28207997 0.69 MEN1 (0.45) L3MBTL1MEN1ALDH1A1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080132481-A1 INTERLEUKIN-4 GENE EXPRESSION INHIBITORS AVENTIS PHARMACEUTICALS INC. 2008-06-05 US claimed
EP-1501797-A1 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS Aventis Pharmaceuticals, Inc. (US) 2005-02-02 EP claimed
US-20040006123-A1 Interleukin-4 gene expression inhibitors AVENTIS PHARMACEUTICALS INC. 2004-01-08 US claimed
WO-2003091214-A1 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO AVENTIS PHARMACEUTICALS INC. (US) 2003-11-06 WO claimed
EP-1501797-B1 3-(SUBSTITUTED AMINO)-1H-INDOLE-2-CARBOXYLIC ACID ESTER AND 3-(SUBSTITUTED AMINO)-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID ESTER DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS AVENTIS PHARMA INC (US) 2009-08-05 EP disclosed
US-20080132481-A1 INTERLEUKIN-4 GENE EXPRESSION INHIBITORS AVENTIS PHARMACEUTICALS INC. 2008-06-05 US disclosed
EP-1834947-A2 3-substituted amino-1H-indole-2-carboxylic acid and 3-substituted amino-benzo[B]thiophene-2carboxylic acid derivatives as interleukin-4 gene expression inhibitors Aventis Pharmaceuticals, Inc. (US) 2007-09-19 EP disclosed
US-7169925-B2 Indole derivatives as interleukin-4 gene expression inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2007-01-30 US disclosed
EP-1501797-A1 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS Aventis Pharmaceuticals, Inc. (US) 2005-02-02 EP disclosed
US-20040010029-A1 Indole derivatives as interleukin -4 gene expression inhibitors AVENTIS PHARMACEUTICALS INC. 2004-01-15 US disclosed
US-20040006123-A1 Interleukin-4 gene expression inhibitors AVENTIS PHARMACEUTICALS INC. 2004-01-08 US disclosed
WO-2003091214-A1 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO AVENTIS PHARMACEUTICALS INC. (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040010029-A1 Indole derivatives as interleukin -4 gene expression inhibitors IL4, IL4I1, STAT4 MAPKAPK2 3833/4885UBE2N 2076/4885L3MBTL1 828/4885
US-20040006123-A1 Interleukin-4 gene expression inhibitors IL4, STAT4, BCL6 MAPKAPK2 3856/4885UBE2N 3040/4885L3MBTL1 930/4885
US-20080132481-A1 INTERLEUKIN-4 GENE EXPRESSION INHIBITORS IL4, STAT4, STAT6 MAPKAPK2 4162/4885UBE2N 2939/4885L3MBTL1 832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.